Shingles Vaccine Market: By Product Type, By Vaccine Type, and Region Forecast 2019-2030

download arrow download arrow Download Free Sample
settings arrow settings arrow email us

Shingles Vaccine Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Shingrix, Sheath, SKYZoster, Others), By Vaccine Type (Recombinant Vaccine, Live Attenuated Vaccine), and Region Forecast 2019-2030

checked icon arrow_drop_down
checked icon Single User License $4400 $3520
checked icon Multiple User License $6600 $5280
checked icon Corporate User License $8900 $7120

Shingles Vaccine Market size was valued at US$ 3.6 billion in 2023 and is expected to reach US$ 14.1 billion by 2030, at a significant CAGR of 13.8% from 2024-2030. Shingles is known as Herpes Zoster which causes a blistering painful rash on the skin which lasts from 2 to 4 weeks. But, for some people, the pain may last for months or years. This pain is called as (PHN) Post Herpetic Neuralgia, which is a common complication of shingles and its occurrence increases with age. There are safe and effective vaccines available for the prevention of shingles. GSK filed regulatory approvals in Europe, Canada, and Japan for Shingrix. The market is a very highly consolidated market with very few market players. It is experiencing rapid growth due to the new products and it may gain swift market growth due to the new entrants into the market during the forecast period.

One key aspect contributing to the global market's overall growth is the increasing number of official recommendations to use these vaccinations. Furthermore, the growing number of senior individuals is predicted to fuel an ever-expanding industry. Many firms have spent a significant amount of money on research and development to create new shingles vaccines. This also contributes to a rise in the number of new product approvals by the FDA. The dangers linked with the vaccine's side effects, on the other hand, are extremely substantial. Furthermore, in poor countries, there is a lack of understanding about the supply and use of these products. In the years ahead, it is possible to pose a threat to the Market's growth.

Shingles Vaccine Market Key Developments

  • In 2006, Merck & Co., Inc. licensed Zostavax for the prevention of shingles which is intended for people above 50 years of age.
  • In 2016, GSK received FDA approval for its Shingrix, a vaccine to prevent shingles which has 90% efficiency in people than Zostavax. 

summary download arrow Download Free Sample

Shingles Vaccine Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

13.9%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Shingles Vaccine Market Dynamics

Increase in the prevalence and incidence of shingles disease around the world and increase in the global ageing population is expected to enhance the growth of shingles vaccine market across the globe. But, lack of awareness, high cost of the vaccination, unfavourable insurance coverage is major restraints of the global market.

Shingles Vaccine Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 3.6 billion

Market Size in 2030

US$ 14.1 billion

Market CAGR

13.9%

By Product Type

  • Live Vaccines
  • Attenuated Vaccines

By Application

  • Herpes Zoster
  • Others

By End User

  • Hospitals
  • Clinic
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)
  • Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)
  • Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

Key Features of the Report

  • The shingles vaccine market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis 

Download Free Sample Report

I accept the Terms and Conditions,Disclaimers, GDPR Policy

Frequently Asked Questions

The shingles vaccine market size was valued at US$ 3.6 billion in 2023 and is projected to reach US$ 14.1 billion by 2030, at a CAGR of 13.8% from 2024 - 2030

The key segments covered in the market are technology, components, application, and end-users.

The market key players are Merck& Co., Inc. (U.S.), GlaxoSmithKline plc (UK), Cipla Inc. (India), Pfizer Inc. (U.S.)

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Shingles Vaccine Market Introduction
2.1. Global Shingles Vaccine Market Taxonomy
2.2. Global Shingles Vaccine Market Definitions
2.2.1. By Product Type
2.2.2. By Vaccine Type
2.2.3. By Region
3. Global Shingles Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Shingles Vaccine Market Dynamic Factors - Impact Analysis
3.6. Impact of COVID-19 on The Market
3.7. Three Forecast Scenarios - Pessimistic, Conservative, and Opportunistic
3.8. Mapping Market Players Activities
3.9. Recent Key Developments
3.10. Financial Status of the Market Players
3.11. Recent Acquisitions, Collaborations, and Mergers
4. Global Shingles Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Shingles Vaccine Market Forecast, By Product Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
5.1. Shingrix
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Zostavax
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. SKYZoster
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Shingles Vaccine Market Forecast, By Vaccine Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
6.1. Recombinant Vaccine
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Live Attenuated Vaccine
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7. Global Shingles Vaccine Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Distribution Channel, Vaccine Type, and Region, 2024 - 2030
8. North America Shingles Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
8.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Shingrix
8.1.2. Sheath
8.1.3. SKYZoster
8.1.4. Others
8.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Recombinant Vaccine
8.2.2. Live Attenuated Vaccine
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
8.3.1. U.S.
8.3.2. Canada
8.4. North America Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2024 - 2030
8.5. North America Shingles Vaccine Market Dynamics Trends
9. Europe Shingles Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
9.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Shingrix
9.1.2. Sheath
9.1.3. SKYZoster
9.1.4. Others
9.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Recombinant Vaccine
9.2.2. Live Attenuated Vaccine
9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Europe Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2024 - 2030
9.5. Europe Shingles Vaccine Market Dynamics Trends
10. Asia-Pacific Shingles Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
10.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Shingrix
10.1.2. Sheath
10.1.3. SKYZoster
10.1.4. Others
10.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Recombinant Vaccine
10.2.2. Live Attenuated Vaccine
10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
10.3.1. Japan
10.3.2. China
10.3.3. India
10.3.4. ASEAN
10.3.5. Rest of Asia-Pacific
10.4. Asia-Pacific Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2024 - 2030
10.5. Asia-Pacific Shingles Vaccine Market Dynamics Trends
11. Latin America Shingles Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
11.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Shingrix
11.1.2. Sheath
11.1.3. SKYZoster
11.1.4. Others
11.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Recombinant Vaccine
11.2.2. Live Attenuated Vaccine
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Argentina
11.3.3. Rest of Latin America
11.4. Latin America Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2024 - 2030
11.5. Latin America Shingles Vaccine Market Dynamics Trends
12. Middle East and Africa Shingles Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Million)
12.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Shingrix
12.1.2. Sheath
12.1.3. SKYZoster
12.1.4. Others
12.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Recombinant Vaccine
12.2.2. Live Attenuated Vaccine
12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Million) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Saudi Arabia
12.3.2. GCC Countries
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Shingles Vaccine Market - Opportunity Analysis Index, By Product Type, Vaccine Type and Country, 2024 - 2030
12.5. MEA Shingles Vaccine Market Dynamics Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Product Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. GlaxoSmithKline plc.
13.2.2. Merck & Co., Inc.
13.2.3. SK chemicals
13.2.4. Green Cross Corp
13.2.5. CanSinoBIO
13.2.6. Geneone Life Science
13.2.7. Vaccitech
13.2.8. Curevo Inc
14. Research Methodology
15. Key Assumptions and Acronyms

Key Market Players

  • Merck& Co., Inc. (U.S.)
  • GlaxoSmithKline plc (UK)
  • Cipla Inc. (India)
  • Pfizer Inc. (U.S.)

Related Industry Reports

Vaccine Vials Market

Malaria Vaccine Market

Global Vaccine Adjuvants Market

Global Influenza Vaccine Market